Zomedica CorpChange company Symbol lookupSelect an option...ZOM Zomedica CorpC Citigroup IncWMT WALMART STORES INCAMANX Amana Mutual Funds Trust Income Fund InvestorBAC Bank of America CorpGMS GMS Inc$VX3MN.X CBOE Near-Term VIX3MTSHA Taysha Gene Therapies IncPTPI Petros Pharmaceuticals IncMGDPF Marathon Gold CorpGo
Zomedica Corp., formerly Zomedica Pharmaceuticals Corp., is a development stage veterinary diagnostic and pharmaceutical company. The Company is engaged in developing products for companion animals, such as canine, feline, and equine by focusing on needs of clinical veterinarians. It is focused on developing three diagnostic platforms, a Bulk Acoustic Wave sensor-based veterinary point-of-care diagnostic platform for performing immunodiagnostic testing, a Raman spectroscopy-based point-of-care diagnostic platform for the detection of pathogens, and liquid biopsy assays for the detection of cancer, along with related consumables. The Company’s TRUFORMA product candidate is an investigational device being developed as a point-of-care biosensor platform. ZM-020 is its diagnostic platform being developed to screen for a range of pathogens in companion animal feces, urine, respiratory, and dermatological samples. It is developing ZM-017 as a canine cancer liquid biopsy platform.
|
|
|
|
| |
Information provided by Copyright © 2021. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.